Selected Publications

Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of Alternate Pro-Survival Pathways Accounts for Acquired Sunitinib Resistance in U87MG Glioma Xenografts. J Pharmacol Exp Ther. 2012 doi:10.1124/jpet.112.196097.

Sharma J, Lv H, Gallo JM. Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. J Pharm Sci. 2012 Aug 1.

Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012 Mar 21;4(126):126ps7.

Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM. Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs. 2012 Mar 1.

Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM. Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal. 2011 Dec 15;56(5):1117-20.

Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.

Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011 Mar;13(1):111-20.

Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010 Dec 6;7(6):2255-69.

Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010 Oct;12(10):1043-9.

Gallo JM. Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med. 2010 Jul-Aug;77(4):381-8.

Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010 Mar 11;51(4):958-64.

Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009 Jun;8(6):1438-47.

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res. 2009 Jan 1;69(1):120-7.

Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic brain tumor model.Neuro Oncol. 2009 Jun;11(3):301-10.

Zhou Q, Guo P, Gallo JM. Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008 Mar 1;14(5):1540-9.

Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008 Feb;7(2):407-17.

Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM. Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal. 2011 Dec 15;56(5):1117-20.

Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.

Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011 Mar;13(1):111-20.

Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010 Dec 6;7(6):2255-69.

Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010 Oct;12(10):1043-9.

Gallo JM. Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med. 2010 Jul-Aug;77(4):381-8.

Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010 Mar 11;51(4):958-64.

Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009 Jun;8(6):1438-47.

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res. 2009 Jan 1;69(1):120-7.

Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic brain tumor model.Neuro Oncol. 2009 Jun;11(3):301-10.

Zhou Q, Guo P, Gallo JM. Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008 Mar 1;14(5):1540-9.

Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008 Feb;7(2):407-17.

Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res. 2007 Jul 15;13(14):4271-9.

Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther. 2007 Apr;321(1):265-75.

Gallo JM, Vicini P, Orlansky A,  Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004 Dec 1;10(23):8048-58.

Gallo JM, Li S, Guo P, Reed K, Ma, J.  The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 2003 Aug 15;63(16):5114-7.

Ma J, Li S, Reed K, Guo P, Gallo JM.  Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide (TMZ) in subcutaneous and intracerebral human glioma xenograft models.  J Pharmacol Exp Ther. 2003 Jun;305(3):833-9.

Ma J, Reed K, Gallo JM.  Cells designed to deliver anticancer drugs by apoptosis. Cancer Res. 2002 Mar 1;62(5):1382-7.

Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic‑mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP‑470.  Cancer Res. 2001 Jul 15;61(14):5491-8.

Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD.  Population pharmacokinetic model for topotecan derived from phase I clinical trials.  J Clin Oncol. 2000 Jun;18(12):2459-67.

Devineni D, Klein‑Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the absence and presence of the angiogenesis inhibitor TNP‑470. Cancer Res. 1996 May 1;56(9):1983-7.

Gallo JM, Brennan J, Halbher T, Laub P, Ozols RF, O'Dwyer PJ. Time‑dependent pharmacodynamic models in cancer chemotherapy:  Population pharmacodynamic model for glutathione depletion following administration of buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res. 1995 Oct 15;55(20):4507-11.